Acumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference

Reuters

2025/07/10

Acumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference

Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is set to present new findings at the Alzheimer's Association International Conference $(AAIC)$ 2025 in Toronto. The presentations will include a cost savings analysis of the use of pTau217 as a screening tool in the company's Phase 2 ALTITUDE-AD trial of the therapeutic agent sabirnetug, as well as a nonclinical study on sabirnetug's selectivity for targeting amyloid beta oligomers (AβOs) compared to amyloid beta monomers. These results will be shared during poster presentations scheduled for July 28 and July 29, 2025, respectively. The studies emphasize sabirnetug's potential efficacy in treating early Alzheimer's disease and its distinct selectivity for toxic AβOs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492029-en) on July 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550474596"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550474596\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550474596?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550474596","market":"nz","top_or_hot":-1,"title":"Acumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is set to present new findings at the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025 in Toronto. The presentations will include a cost savings analysis of the use of pTau217 as a screening tool in the company's Phase 2 ALTITUDE-AD trial of the therapeutic agent sabirnetug, as well as a nonclinical study on sabirnetug's selectivity for targeting amyloid beta oligomers (AβOs) compared to amyloid beta monomers. These results will be shared during poster presentations scheduled for July 28 and July 29, 2025, respectively. The studies emphasize sabirnetug's potential efficacy in treating early Alzheimer's disease and its distinct selectivity for toxic AβOs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492029-en) on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-10 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Acumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is set to present new findings at the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025 in Toronto. The presentations will include a cost savings analysis of the use of pTau217 as a screening tool in the company's Phase 2 ALTITUDE-AD trial of the therapeutic agent sabirnetug, as well as a nonclinical study on sabirnetug's selectivity for targeting amyloid beta oligomers (AβOs) compared to amyloid beta monomers. These results will be shared during poster presentations scheduled for July 28 and July 29, 2025, respectively. The studies emphasize sabirnetug's potential efficacy in treating early Alzheimer's disease and its distinct selectivity for toxic AβOs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492029-en) on July 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL4khxkk:1","article_id":"2550474596","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550474596","pubTimestamp":1752148831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is set to present new findings at the Alzheimer's Association International Conference  2025 in Toronto. The presentations will include a cost savings analysis of the use of pTau217 as a screening tool in the company's Phase 2 ALTITUDE-AD trial of the therapeutic agent sabirnetug, as well as a nonclinical study on sabirnetug's selectivity for targeting amyloid beta oligomers  compared to amyloid beta monomers. These results will be shared during poster presentations scheduled for July 28 and July 29, 2025, respectively. The studies emphasize sabirnetug's potential efficacy in treating early Alzheimer's disease and its distinct selectivity for toxic AβOs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4539":"次新股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ABOS":"Acumen Pharmaceuticals, Inc."},"translate_title":"Acumen Pharmaceuticals在2025年AAIC会议上推出了新的节省成本的2期阿尔茨海默病研究筛查检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ABOS":0.9},"content_text":"Acumen Pharmaceuticals Unveils New Cost-Saving Screening Assay in Phase 2 Alzheimer's Study at 2025 AAIC Conference\n    \n\n        Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is set to present new findings at the Alzheimer's Association International Conference $(AAIC)$ 2025 in Toronto. The presentations will include a cost savings analysis of the use of pTau217 as a screening tool in the company's Phase 2 ALTITUDE-AD trial of the therapeutic agent sabirnetug, as well as a nonclinical study on sabirnetug's selectivity for targeting amyloid beta oligomers (AβOs) compared to amyloid beta monomers. These results will be shared during poster presentations scheduled for July 28 and July 29, 2025, respectively. The studies emphasize sabirnetug's potential efficacy in treating early Alzheimer's disease and its distinct selectivity for toxic AβOs.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9492029-en) on July 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}